2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
April 21st, 2025
Version: 1
Gustave Roussy
cancer biology
biorxiv

NOX4 prevents the recruitment of PAX8 and NKX2.1 to chromatin in BRAF-mutated thyroid cancer cells.

Radom, M.Open in Google Scholar•Buffet, C.Open in Google Scholar•Cazarin, J.Open in Google Scholar•Harinquet, M.Open in Google Scholar•Coelho de Faria, C.Open in Google Scholar•Braye, F.Open in Google Scholar•Nobre, C.Open in Google Scholar•Aglave, M.Open in Google Scholar•Mesloub, Y.Open in Google Scholar•Dayris, T.Open in Google Scholaret al.

Radioiodine (RAI) therapy, used for treating thyroid cancers, hinges on the expression of the Sodium Iodide Symporter (NIS). The majority of differentiated thyroid cancers (DTCs) are papillary, with a BRAFV600E mutation. This mutation correlates with an absence of RAI uptake, due to low NIS expression and a low differentiation score. NADPH oxidase 4 (NOX4)-derived ROS contribute to NIS repression in BRAFV600E-mutated thyroid cancer cells. Depleting NOX4 enhances the reactivation of NIS. This reversibility implies an epigenetic mechanism's contribution. Our findings indicate that NOX4 generates oxidative DNA damage in BRAFV600E-mutated thyroid cancer cells. DNA repair proteins such as OGG1 and MSH2/MSH6 proteins, in cooperation with DNMT1, turn these damages into transcription-blocking damages. This prevents the binding of PAX8 and NKX2.1 - two key transcription factors involved in thyroid differentiation - to the chromatin. Co-inhibition of the MAPK pathway, which regulates MSH2/MSH6 and DNMT1 expressions, and the TGF-beta1 pathway, which regulates NOX4 expression, fortifies the recruitment of the two transcription factors to the chromatin. Collectively, our findings present a molecular basis for NOX4's role in thyroid dedifferentiation

Similar Papers

biorxiv
Mon Apr 21 2025
The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.
Ribosome biogenesis (RiBi) is a key determinant of cell growth and proliferation and is highly elevated in cancer due to the activation by oncogenes such as MYC. First-generation RiBi inhibitor CX-5461, while demonstrating clinical potential for cancer treatment, also induces DNA damage through off-target inhibition of TOP2 and potentially other mechanisms, bringing into question RiBi as a target ...
Ferreira, R.
•
Hannan, K. M.
•
Panov, K.
•
Udumanne, T.
...•
Hein, N.
biorxiv
Mon Apr 21 2025
Single-Cell Pharmacogenomic Landscapes of Epigenetic Therapy in Gastric Cancer
Gene expression signatures (\"molecular phenotypes\") are extensively utilized in cancer research. Using direct capture Perturb-seq (dcPerturb-seq), we surveyed how molecular phenotypes in gastric cancer (GC) are shaped by cell-intrinsic genetic alterations interacting with cell-extrinsic therapeutic exposures. Interrogating >200 GC-related genes against 4 distinct epigenetic drug classes across m...
Xu, C.
•
Ma, H.
•
Sheng, T.
•
Lee, M. H.
...•
Tan, P.
biorxiv
Mon Apr 21 2025
The lnc-FANCI-2 intrinsically restricts RAS signaling in HPV16-infected cervical cancer
We recently discovered the expression of a long noncoding RNA, lnc-FANCI-2, coinciding with cervical lesion progression from CIN1, CIN2-3 to cervical cancer. Viral E7 of high-risk HPVs and host transcription factor YY1 are two major factors promoting lnc-FANCI-2 expression. To explore possible roles of lnc-FANCI-2 in HPV-induced cervical carcinogenesis, we ablated the expression of lnc-FANCI-2 in ...
Liu, H.
•
Yu, L.
•
Majerciak, V.
•
Meyer, T.
...•
Zheng, Z.-M.
biorxiv
Mon Apr 21 2025
A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity
The RNA-binding protein IGF2BP3 is an oncofetal protein overexpressed in B-acute lymphoblastic leukemia and is critical for leukemogenesis in experimental models. With cancer-specific expression, functional dispensability for normal development, and an unleveraged pro-oncogenic function in mRNA homeostasis, IGF2BP3 represents an excellent target. With no small molecule inhibitors of IGF2BP3 in cli...
Jaiswal, A. K.
•
Scherer, G. M.
•
Thaxton, M. L.
•
Sorrentino, J. P.
...•
Rao, D. S.
biorxiv
Fri Apr 18 2025
New Δ246p53 isoform responds to DNA damage to enhance p53 functions in senescence and tumour suppression
p53 is with little doubt one of the most powerful genes in our genome, as it makes growth vs arrest, repair vs replacement, metabolism vs anabolism, life vs death decisions in the cell. An alteration or malfunction in p53 may lead to cancer or premature ageing. So, it is not surprising that p53 is also one of the most complex and tightly regulated genes. p53 alone encodes for at least 10 RNA varia...
Parkar, S. N.
•
Ramalho, A. C.
•
Lopez-Iniesta, M. J.
•
Kimura, K.
...•
Candeias, M. M.
biorxiv
Fri Apr 18 2025
SKIDA1 transiently sustains MLL::ENL-Expressing hematopoietic progenitors during neonatal stages and promotes B-lineage priming
Infant leukemias arise as B-cell acute lymphocytic (B-ALL) or acute myeloid leukemia (AML). The majority are driven by chromosomal rearrangements of the MLL/ KMT2A gene (MLLr) and arise in utero, implying a fetal cell of origin. Fetal and neonatal hematopoietic progenitors have unique transcriptomes and epigenomes, raising the question of whether MLL fusion proteins activate distinct target gene p...
Mendoza-Castrejon, J.
•
Yang, W.
•
Denby, E.
•
Muthukumar, R.
...•
Magee, J. A.
biorxiv
Fri Apr 18 2025
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Our understanding of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) primarily stems from murine models or primary patient tumors. While metastatic tumors have generally less immune infiltration compared to primary tumors, the specific cellular features of metastatic PDAC remain understudied. This knowledge gap is impactful as most patients present with metastatic disease ...
Greene, E.
•
Horvat, N. K.
•
Doxie, D. B.
•
Parihar, V. C.
...•
Lesinski, G. B.
biorxiv
Fri Apr 18 2025
Potentiation of EGFR mutant lung cancer treatment targeting replication stress.
Oncogene-targeted therapies against growth factor receptors are effective treatment options for driver mutation-positive non-small cell lung cancer (NSCLC). The third-generation EGFR-Tyrosine Kinase inhibitor (TKI) osimertinib, is a standard first-line therapy for patients with EGFR-mutated NSCLC cancer. Acquired resistance to osimertinib is a significant problem that limits survival. In addition ...
Bhowmick, R.
•
Turchi, J. J.
•
Jalal, S. I.
biorxiv
Fri Apr 18 2025
CLM296: a highly selective inhibitor targeting ALDH1A3-driven tumor growth and metastasis in breast cancer
Aldehyde dehydrogenase 1A3 (ALDH1A3) increases tumor growth, metastasis, and chemoresistance in many solid tumors, including triple-negative breast cancer (TNBC), glioblastoma, melanoma, lung, and colon cancers, yet no clinically approved inhibitors exist. Here, we present CLM296, a novel and highly selective ALDH1A3 inhibitor designed to address this unmet need. CLM296 exhibits potent inhibition ...
MacLean, M. R.
•
Bernardoni, B. L.
•
Fernando, W.
•
Petrarolo, G.
...•
Marcato, P.